Epizyme (EPZM) Tops Q4 EPS by 19c

Epizyme (NASDAQ: EPZM) reported Q4 EPS of ($0.29), $0.19 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $8 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Halozyme adds biotech executive Appelhans to its board
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business